https://pharminent.com/week-in-review/week-in-review-intelligence-brief-april-25-2026/ 2026-04-25T23:45:27Z Pharminent en Week in Review • INTELLIGENCE BRIEF • April 25, 2026 2026-04-25T23:45:24Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-april-24-2026/ 2026-04-25T21:29:27Z Pharminent en GLP-1 Competitive Market Digest • Weekly • April 24, 2026 2026-04-25T21:27:29Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-april-24-2026/ 2026-04-25T20:27:32Z Pharminent en Oncology Intelligence Digest • April 24, 2026 2026-04-25T20:27:29Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-april-22-2026/ 2026-04-25T20:24:47Z Pharminent en Manufacturing Intelligence • Weekly Digest • April 22, 2026 2026-04-25T20:24:43Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-april-22-2026/ 2026-04-25T20:22:59Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • April 22, 2026 2026-04-25T20:22:56Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-april-17-2026/ 2026-04-24T20:05:30Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • April 17, 2026 2026-04-24T20:05:12Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-april-24-2026/ 2026-04-24T20:04:08Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • April 24, 2026 2026-04-24T20:04:04Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-24-2026/ 2026-04-24T20:01:15Z Pharminent en Strategic News Watch • April 24, 2026 2026-04-24T20:01:11Z Blog https://pharminent.com/regulatory-round-up-novartis-sanofi-and-arrowhead-secure-chmp-blessings/ 2026-04-24T16:08:43Z Pharminent en Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings 2026-04-24T13:45:58Z Blog https://pharminent.com/daiichi-sankyo-shares-slip-after-delaying-annual-earnings-report/ 2026-04-24T16:08:46Z Pharminent en Daiichi Sankyo shares slip after delaying annual earnings report 2026-04-24T12:44:59Z Blog https://pharminent.com/pfizer-culls-early-pd-l1-asset-after-series-of-clinical-wins-deals-in-cancer/ 2026-04-24T16:08:48Z Pharminent en Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer 2026-04-24T12:44:24Z Blog https://pharminent.com/avalyn-seeks-public-debut-to-support-new-lung-drug-formulations/ 2026-04-25T21:23:14Z Pharminent en Avalyn seeks public debut to support new lung drug formulations 2026-04-24T12:02:00Z Blog https://pharminent.com/beyond-formulary-access-building-a-scalable-pharmaceutical-manufacturer-commercial-platform-for-direct-to-consumer-and-employer-channels/ 2026-04-24T16:08:52Z Pharminent en Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels 2026-04-24T11:00:00Z Blog https://pharminent.com/ozmosi-and-planview-partner-to-enhance-pharmaceutical-data-integration/ 2026-04-25T20:44:03Z Pharminent en OZMOSI and Planview partner to enhance pharmaceutical data integration 2026-04-24T10:54:29Z Blog https://pharminent.com/cardiometabolic-trials-using-expertise-to-turn-complexity-into-robust-results/ 2026-04-25T20:45:48Z Pharminent en Cardiometabolic trials: Using expertise to turn complexity into robust results 2026-04-24T10:36:17Z Blog https://pharminent.com/regeneron-cuts-white-house-pricing-deal-offers-new-gene-therapy-for-free/ 2026-04-24T16:08:55Z Pharminent en Regeneron cuts White House pricing deal, offers new gene therapy for free 2026-04-24T10:12:25Z Blog https://pharminent.com/cumberland-to-sell-drug-portfolio-to-apotex-for-100m/ 2026-04-24T16:08:56Z Pharminent en Cumberland to sell drug portfolio to Apotex for $100m 2026-04-24T09:33:03Z Blog https://pharminent.com/fda-clears-first-genetic-hearing-loss-gene-therapy/ 2026-04-24T16:08:56Z Pharminent en FDA clears first genetic hearing loss gene therapy 2026-04-24T09:22:53Z Blog https://pharminent.com/cumberland-to-sell-drug-portfolio-to-apotex-for-100m-2/ 2026-04-24T16:08:57Z Pharminent en Cumberland to sell drug portfolio to Apotex for $100m 2026-04-24T09:14:46Z Blog